"GLIMITERIS M1: Dual-Action Diabetes Control"

GLIMITERIS M1 

Glimepiride & Metformin Hydrochloride Prolonged Release

Introduction to GLIMITERIS M1

GLIMITERIS M1 combines Glimepiride and Metformin Hydrochloride in a prolonged-release formula, offering an innovative solution for managing type 2 diabetes. This combination therapy targets various aspects of diabetes control, enhancing glucose regulation and minimizing the risk of associated complications.

Usage and Benefits of GLIMITERIS M1

Comprehensive Blood Sugar Control

• Dual Mechanism of Action: Glimepiride increases insulin secretion, while Metformin reduces glucose production in the liver.
• Prolonged Release Formula: Ensures steady medication levels in the body for consistent blood sugar control.

Enhanced Patient Convenience

• Once-Daily Dosing: Simplifies treatment regimen, improving patient adherence.
• Reduced Side Effects: The prolonged-release formula minimizes gastrointestinal side effects common with Metformin.

Cardiovascular Benefits

• Improved Lipid Profile: GLIMITERIS M1 can lead to improvements in cholesterol and triglyceride levels.
• Blood Pressure Reduction: May have a beneficial effect on blood pressure in patients with type 2 diabetes.

Weight Management

• Weight Neutral or Loss: Unlike other diabetic medications, GLIMITERIS M1 does not typically lead to weight gain and may assist in weight loss.

Long-Term Health Outcomes

• Reduced Risk of Diabetic Complications: Continuous use of GLIMITERIS M1 can lower the risk of diabetes-related complications like neuropathy, retinopathy, and nephropathy.
• Enhanced Quality of Life: Effective management of blood glucose levels can lead to improved overall well-being and daily functioning.

Optimizing Treatment with GLIMITERIS M1

Individualized Therapy

• Tailored Dosing: GLIMITERIS M1 can be adjusted to meet individual patient needs, ensuring optimal glycemic control.
• Comprehensive Management: Should be part of a broader diabetes management plan, including diet, exercise, and regular monitoring.

Monitoring and Follow-Up

• Regular monitoring of blood glucose levels and periodic A1C testing will help assess the effectiveness of GLIMITERIS M1 and guide potential treatment adjustments.

In summary, GLIMITERIS M1 represents a significant advancement in the treatment of type 2 diabetes, offering a dual mechanism of action for improved glycemic control, convenience, and the potential for better long-term health outcomes. Its unique prolonged-release formulation enhances patient adherence and quality of life, making it a cornerstone in diabetes management strategies. A team of highly skilled professionals in the pharmaceutical field established Steris Healthcare Pvt Ltd in February 2018. Sterispharma is a certified pharmaceutical company by WHO, GMP, and ISO, situated in Navi Mumbai. It is dedicated to delivering high-quality medications at competitive prices to customers across India, adhering to WHO's stringent standards. Through Steris's online pharmacy, customers can conveniently purchase medicines and receive home delivery. Our primary objective at Steris is to offer a comprehensive range of healthcare products to fulfill the diverse requirements of the healthcare industry. Steris is committed to meeting the healthcare sector's demands, whether it's specialized treatments, medications for rare diseases, or essential pharmaceuticals. The range of Steris healthcare products caters to various medical needs, including Cardiology, Asthma, Respiratory, Nasal, Diabetes, Endocrinology, Gastrology, Orthopedics, Anti-infective/antibiotics, General Medicine, Urology, Neurology, Nephrology, Oncology, Gynecology, Pediatrics, Dental, and Dermatology.  For further information:  EMAIL:  info@sterispharma.com  / contact@sterispharma.com     CALL/WHATSAPP:: 7877551268, 8209542042, 8955945010, 6377716668   

  BUY NOW